Medicare Enrolled
Dr. Prasad Dighe, MD
Optician · Stockton, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Dighe from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Dighe?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Dighe
Dr. Prasad Dighe is an optician specialist in Stockton, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Dighe performed 26,525 Medicare services across 1,298 unique beneficiaries.
Between the years covered by Open Payments, Dr. Dighe received a total of $12,257 from 81 pharmaceutical and/or device companies across 567 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Dighe is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 4% volume in CA
$12,257 industry payments
Medicare Practice Summary
Medicare Utilization ↗26,525
Medicare services
Top 4% in CA for optician
1,298
Unique beneficiaries
$19
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,396 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
13,260 | $0 | $16 |
| Denosumab injection (Prolia/Xgeva) | 8,220 | $18 | $69 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,408 | $0 | $17 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
693 | $100 | $389 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
359 | $11 | $47 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
324 | $8 | $32 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
305 | $111 | $407 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
237 | $24 | $91 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
178 | $67 | $274 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
170 | $8 | $26 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
161 | $1 | $30 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
147 | $65 | $225 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
140 | $13 | $53 |
| Piflufolastat F-18 diagnostic injection A diagnostic injection of the radioactive tracer piflufolastat F-18 used for imaging. The dose specified is 1 millicurie. |
126 | $475 | $2,336 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
125 | $28 | $103 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
81 | $23 | $88 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
81 | $54 | $210 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
78 | $1,355 | $4,995 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
74 | $53 | $199 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
71 | $125 | $487 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
69 | $18 | $84 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 66 | $278 | $1,110 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
63 | $1 | $33 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
40 | $141 | $503 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
25 | $149 | $553 |
| New patient office visit, complex (60-74 min) | 24 | $166 | $690 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
52.6% high complexity
40.6% medium
6.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$12,257
Total received (2018-2024)
Avg $1,751/year across 7 years
Top 12% in CA for optician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
81
Companies
567
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,582 (70.0%)
Other
Charitable contributions, space rental, and other categories
$2,123 (17.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,551 (12.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,202
2023
$2,006
2022
$2,291
2021
$2,780
2020
$733
2019
$1,308
2018
$937
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$325
ABBVIE INC.
$183
Celgene Corporation
$151
AstraZeneca Pharmaceuticals LP
$143
Janssen Biotech, Inc.
$119
Regeneron Healthcare Solutions, Inc.
$117
PFIZER INC.
$113
E.R. Squibb & Sons, L.L.C.
$112
Lilly USA, LLC
$109
BeiGene USA, Inc.
$107
ARRAY BIOPHARMA INC
$102
Takeda Pharmaceuticals U.S.A., Inc.
$90
Genentech USA, Inc.
$90
SpringWorks Therapeutics, Inc.
$63
Gilead Sciences, Inc.
$38
Pharmacosmos Therapeutics Inc.
$37
GlaxoSmithKline, LLC.
$32
TAIHO ONCOLOGY, INC.
$31
Eisai Inc.
$30
Deciphera Pharmaceuticals Inc.
$26
Incyte Corporation
$25
Kyowa Kirin, Inc.
$24
SERVIER PHARMACEUTICALS LLC
$23
Agios Pharmaceuticals, Inc.
$22
Merck Sharp & Dohme LLC
$21
Fennec Pharmaceuticals, Inc.
$19
Myriad Genetic Laboratories, Inc.
$17
Coherus Biosciences Inc.
$17
Amgen Inc.
$14
Top 3 companies account for 29.9% of 2024 payments
All-time payments by company (2018-2024) ›
NOVARTIS PHARMACEUTICALS CORPORATION
$1,317
Janssen Biotech, Inc.
$1,004
Novartis Pharmaceuticals Corporation
$940
E.R. Squibb & Sons, L.L.C.
$776
PFIZER INC.
$606
Amgen Inc.
$579
Astellas Pharma US Inc
$468
Seagen Inc.
$437
AstraZeneca Pharmaceuticals LP
$411
Genentech USA, Inc.
$350
Celgene Corporation
$324
Pharmacyclics LLC, An AbbVie Company
$289
Kite Pharma, Inc.
$283
Lilly USA, LLC
$271
ABBVIE INC.
$246
GENZYME CORPORATION
$243
Incyte Corporation
$229
Gilead Sciences, Inc.
$222
Merck Sharp & Dohme Corporation
$194
ARRAY BIOPHARMA INC
$180
BeiGene USA, Inc.
$166
Regeneron Healthcare Solutions, Inc.
$145
Takeda Pharmaceuticals U.S.A., Inc.
$136
Clovis Oncology, Inc.
$120
Rigel Pharmaceuticals, Inc.
$115
Merck Sharp & Dohme LLC
$110
Janssen Scientific Affairs, LLC
$95
Daiichi Sankyo Inc.
$85
GlaxoSmithKline, LLC.
$77
Myovant Sciences Inc.
$76
Kyowa Kirin, Inc.
$73
Janssen Pharmaceuticals, Inc
$66
SpringWorks Therapeutics, Inc.
$63
Bayer HealthCare Pharmaceuticals Inc.
$61
SERVIER PHARMACEUTICALS LLC
$60
Dendreon Pharmaceuticals LLC
$54
Eisai Inc.
$53
Puma Biotechnology, Inc.
$52
Blueprint Medicines Corporation
$49
TAIHO ONCOLOGY, INC.
$48
Deciphera Pharmaceuticals Inc.
$47
Blue Earth Diagnostics Limited
$47
TerSera Therapeutics LLC
$44
MorphoSys, US Inc.
$43
AbbVie, Inc.
$41
Exelixis Inc.
$41
Shire North American Group Inc
$40
Octapharma USA, Inc.
$39
EMD Serono, Inc.
$38
Pharmacosmos Therapeutics Inc.
$37
Teva Pharmaceuticals USA, Inc.
$37
Myriad Genetic Laboratories, Inc.
$37
Jazz Pharmaceuticals Inc.
$37
Seattle Genetics, Inc.
$37
Medtronic, Inc.
$33
Stemline Therapeutics Inc.
$33
CTI BioPharma Corp.
$33
Pharmacyclics LLC, an AbbVie Company
$30
AVEO Pharmaceuticals, Inc.
$28
Aurobindo Pharma USA, Inc.
$28
Secura Bio, Inc.
$27
Mirati Therapeutics, Inc.
$26
Ipsen Biopharmaceuticals, Inc
$25
AbbVie Inc.
$24
Sobi, Inc
$24
JAZZ PHARMACEUTICALS INC.
$24
Boehringer Ingelheim Pharmaceuticals, Inc.
$24
Sumitomo Pharma America, Inc.
$23
Agios Pharmaceuticals, Inc.
$22
Servier Pharmaceuticals LLC
$21
Karyopharm Therapeutics Inc.
$21
AMAG Pharmaceuticals, Inc.
$21
Fennec Pharmaceuticals, Inc.
$19
Epizyme, Inc.,
$19
Bayer Healthcare Pharmaceuticals Inc.
$18
Coherus Biosciences Inc.
$17
Heron Therapeutics, Inc.
$17
EISAI INC.
$16
Helsinn Therapeutics (U.S.), Inc.
$16
R-Pharm US LLC
$15
MEDIVATION FIELD SOLUTIONS LLC
$12
Top 3 companies account for 26.6% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · Abraxane · Axumin · BAVENCIO · BENDEKA · BOSULIF · BRACANALYSIS CDX · BRAFTOVI · BRUKINSA · CABLIVI · CALQUENCE · COPIKTRA · COSELA · CRESEMBA · CYRAMZA · Cabometyx · Cinvanti · DARZALEX · DOPTELET · ELITEK · ELREXFIO · ELZONRIS · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · EVENITY · EXKIVITY · Enhertu · Erleada · FERAHEME · FOTIVDA · FRUZAQLA · Fabhalta · Farydak · Folotyn · GAVRETO · GAZYVA · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Idhifa · Imbruvica · Ixempra · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OBIZUR · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · OJJAARA · ONUREG · OPDIVO · ORGOVYX · OSTEOCOOL RF ABLATION SYSTEM · PADCEV · POTELIGEO · PROMACTA · PROVENGE · Padcev · Pedmark · Perjeta · Phesgo · Polivy · Pomalyst · Poteligeo · PreciseTumor · QINLOCK · REBLOZYL · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · SUTENT · TABRECTA · TAGRISSO · TALVEY · TALZENNA · TASIGNA · TAZVERIK · TECENTRIQ · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Tibsovo · Trodelvy · Udenyca · VENCLEXTA · VERZENIO · VYXEOS · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA · Zevalin · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (70%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Opticians within 10 mi
84
Per 100K population
10.7
County median income
$88,531
Nearest hospital
ST JOSEPH'S MEDICAL CENTER OF STOCKTON
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Dighe is a mixed practice specialist, with above-average Medicare volume (top 4% in CA), with low-engagement industry engagement in the top 12% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Dighe experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Dighe performed 13,260 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Dighe receive payments from pharmaceutical companies?
Yes. Dr. Dighe received a total of $12,257 from 81 companies across 567 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Dighe's costs compare to other opticians in Stockton?
Dr. Dighe's average Medicare payment per service is $19. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Dighe) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Stockton
Browse opticians in Stockton ranked by procedure volume and transparency data.
Highest volume
Top Opticians in CA
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in CA
Which CA opticians receive the most from drug and device companies.
By company
NOVARTIS PHARMACEUTICALS CORPORATION Payments to Doctors
See all physicians who received payments from NOVARTIS PHARMACEUTICALS CORPORATION.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology